ReviewJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026
Advances in VT ablation for arrhythmogenic cardiomyopathy: evidence, mapping and ablation strategies, and predictive factors.
Review in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catheter ablation of ventricular tachycardia (VT) in arrhythmogenic cardiomyopathy (ACM) is a crucial yet challenging procedure, given the evolving disease definitions, diverse subtypes, genetic variability, complexities in risk stratification, and the intricate substrate distribution characteristic of this condition. Initially described as a right ventricular cardiomyopathy (ARVC), ACM now encompasses left-dominant (ALVC) and biventricular (ABVC) phenotypes, driven by desmosomal (e.g., DSP, PKP2) and non-desmosomal (e.g., FLNC, LMNA) mutations, with fibrosis as the primary arrhythmic substrate. Catheter ablation, particularly combined endocardial-epicardial approaches, reduces VT burden but faces high recurrence rates in younger patients and those with extensive scarring. In this review, we critically assess the role of VT ablation in ACM, current evidence, available techniques for mapping and ablation, outcomes and predictors of success of the ablation procedure in this patient group.
Indexed as
Identifiers
41144124What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.